Cargando…
The Effect of Prucalopride on the Completion Rate and Polyp Detection Rate of Colon Capsule Endoscopies
PURPOSE: To investigate whether the prokinetic prucalopride increases the completion rate of colon capsule endoscopy (CCE). Secondary outcomes included demographic distribution, polyp detection rate (PDR), distribution of Leighton–Rex grade, and adverse events. PATIENTS AND METHODS: In a nested coho...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985819/ https://www.ncbi.nlm.nih.gov/pubmed/35401015 http://dx.doi.org/10.2147/CLEP.S353527 |
_version_ | 1784682424492359680 |
---|---|
author | Deding, Ulrik Kaalby, Lasse Baatrup, Gunnar Kobaek-Larsen, Morten Thygesen, Marianne Kirstine Epstein, Owen Bjørsum-Meyer, Thomas |
author_facet | Deding, Ulrik Kaalby, Lasse Baatrup, Gunnar Kobaek-Larsen, Morten Thygesen, Marianne Kirstine Epstein, Owen Bjørsum-Meyer, Thomas |
author_sort | Deding, Ulrik |
collection | PubMed |
description | PURPOSE: To investigate whether the prokinetic prucalopride increases the completion rate of colon capsule endoscopy (CCE). Secondary outcomes included demographic distribution, polyp detection rate (PDR), distribution of Leighton–Rex grade, and adverse events. PATIENTS AND METHODS: In a nested cohort within the CareForColon2015 trial, a subgroup of 406 individuals underwent CCE in 2021. The first half (control) received the standard bowel preparation and the second half (prucalopride) was supplemented with 2 mg of prucalopride. Transit times and bowel preparations were analyzed and completion rates calculated as those having timely transit and acceptable bowel cleanliness. Major adverse events were recorded continuously and minor adverse events were quantified from questionnaires. RESULTS: The group demographics were homogenous. The prevalence ratio for complete CCE was 1.32 (CI 95% 1.15; 1.53) in the prucalopride group compared to the control group. Completion rate was 74.9% in the prucalopride group and 56.7% in the control group. The proportions of acceptable bowel preparation and complete transits were higher in the prucalopride group. The mean CCE transit time was 2 hours and 8 minutes faster in the prucalopride group. The PDR was higher in the intervention group with 55.7% compared to 36.0% in the control group for polyps greater than 9 mm, whereas the groups’ PDRs were similar for small and diminutive polyps. In all, 589 polyps (mean 2.9) were found in the prucalopride group compared to 522 polyps (mean 2.6) in the control group. CONCLUSION: Prucalopride led to an increase in CCE completion rates. The proportions of complete transits and acceptable bowel preparations were higher in the prucalopride group. The PDR was higher in the prucalopride group compared to the control group. No major adverse events were identified. Nausea, diarrhea, headache and fatigue were more commonly reported in the prucalopride group. |
format | Online Article Text |
id | pubmed-8985819 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-89858192022-04-07 The Effect of Prucalopride on the Completion Rate and Polyp Detection Rate of Colon Capsule Endoscopies Deding, Ulrik Kaalby, Lasse Baatrup, Gunnar Kobaek-Larsen, Morten Thygesen, Marianne Kirstine Epstein, Owen Bjørsum-Meyer, Thomas Clin Epidemiol Original Research PURPOSE: To investigate whether the prokinetic prucalopride increases the completion rate of colon capsule endoscopy (CCE). Secondary outcomes included demographic distribution, polyp detection rate (PDR), distribution of Leighton–Rex grade, and adverse events. PATIENTS AND METHODS: In a nested cohort within the CareForColon2015 trial, a subgroup of 406 individuals underwent CCE in 2021. The first half (control) received the standard bowel preparation and the second half (prucalopride) was supplemented with 2 mg of prucalopride. Transit times and bowel preparations were analyzed and completion rates calculated as those having timely transit and acceptable bowel cleanliness. Major adverse events were recorded continuously and minor adverse events were quantified from questionnaires. RESULTS: The group demographics were homogenous. The prevalence ratio for complete CCE was 1.32 (CI 95% 1.15; 1.53) in the prucalopride group compared to the control group. Completion rate was 74.9% in the prucalopride group and 56.7% in the control group. The proportions of acceptable bowel preparation and complete transits were higher in the prucalopride group. The mean CCE transit time was 2 hours and 8 minutes faster in the prucalopride group. The PDR was higher in the intervention group with 55.7% compared to 36.0% in the control group for polyps greater than 9 mm, whereas the groups’ PDRs were similar for small and diminutive polyps. In all, 589 polyps (mean 2.9) were found in the prucalopride group compared to 522 polyps (mean 2.6) in the control group. CONCLUSION: Prucalopride led to an increase in CCE completion rates. The proportions of complete transits and acceptable bowel preparations were higher in the prucalopride group. The PDR was higher in the prucalopride group compared to the control group. No major adverse events were identified. Nausea, diarrhea, headache and fatigue were more commonly reported in the prucalopride group. Dove 2022-04-02 /pmc/articles/PMC8985819/ /pubmed/35401015 http://dx.doi.org/10.2147/CLEP.S353527 Text en © 2022 Deding et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Deding, Ulrik Kaalby, Lasse Baatrup, Gunnar Kobaek-Larsen, Morten Thygesen, Marianne Kirstine Epstein, Owen Bjørsum-Meyer, Thomas The Effect of Prucalopride on the Completion Rate and Polyp Detection Rate of Colon Capsule Endoscopies |
title | The Effect of Prucalopride on the Completion Rate and Polyp Detection Rate of Colon Capsule Endoscopies |
title_full | The Effect of Prucalopride on the Completion Rate and Polyp Detection Rate of Colon Capsule Endoscopies |
title_fullStr | The Effect of Prucalopride on the Completion Rate and Polyp Detection Rate of Colon Capsule Endoscopies |
title_full_unstemmed | The Effect of Prucalopride on the Completion Rate and Polyp Detection Rate of Colon Capsule Endoscopies |
title_short | The Effect of Prucalopride on the Completion Rate and Polyp Detection Rate of Colon Capsule Endoscopies |
title_sort | effect of prucalopride on the completion rate and polyp detection rate of colon capsule endoscopies |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985819/ https://www.ncbi.nlm.nih.gov/pubmed/35401015 http://dx.doi.org/10.2147/CLEP.S353527 |
work_keys_str_mv | AT dedingulrik theeffectofprucaloprideonthecompletionrateandpolypdetectionrateofcoloncapsuleendoscopies AT kaalbylasse theeffectofprucaloprideonthecompletionrateandpolypdetectionrateofcoloncapsuleendoscopies AT baatrupgunnar theeffectofprucaloprideonthecompletionrateandpolypdetectionrateofcoloncapsuleendoscopies AT kobaeklarsenmorten theeffectofprucaloprideonthecompletionrateandpolypdetectionrateofcoloncapsuleendoscopies AT thygesenmariannekirstine theeffectofprucaloprideonthecompletionrateandpolypdetectionrateofcoloncapsuleendoscopies AT epsteinowen theeffectofprucaloprideonthecompletionrateandpolypdetectionrateofcoloncapsuleendoscopies AT bjørsummeyerthomas theeffectofprucaloprideonthecompletionrateandpolypdetectionrateofcoloncapsuleendoscopies AT dedingulrik effectofprucaloprideonthecompletionrateandpolypdetectionrateofcoloncapsuleendoscopies AT kaalbylasse effectofprucaloprideonthecompletionrateandpolypdetectionrateofcoloncapsuleendoscopies AT baatrupgunnar effectofprucaloprideonthecompletionrateandpolypdetectionrateofcoloncapsuleendoscopies AT kobaeklarsenmorten effectofprucaloprideonthecompletionrateandpolypdetectionrateofcoloncapsuleendoscopies AT thygesenmariannekirstine effectofprucaloprideonthecompletionrateandpolypdetectionrateofcoloncapsuleendoscopies AT epsteinowen effectofprucaloprideonthecompletionrateandpolypdetectionrateofcoloncapsuleendoscopies AT bjørsummeyerthomas effectofprucaloprideonthecompletionrateandpolypdetectionrateofcoloncapsuleendoscopies |